Published on 07 July 2016
2016/2 GaBI Journal Table of Contents
2.902 views
Published on 07 July 2016
2.902 views
Published on 06 July 2016
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2016.0502.022
7.532 views
Published on 06 July 2016
Author(s): Benedicte Lunddahl, DVM
biological medicinal products, biosimilars, national competent authority, pharmacovigilance
DOI: 10.5639/gabij.2016.0503.030
10.720 views
Published on 04 July 2016
Author(s): Professor Philip D Walson, MD
DOI: 10.5639/gabij.2016.0502.013
3.961 views
Published on 04 July 2016
Author(s): Carlo Piccinni, PhD, Federico Fontolan, MA, Silvia Zucconi, MStat
economic sustainability, generic medicines, manufacturing provision, pharmacoeconomics
DOI: 10.5639/gabij.2016.0503.029
14.317 views
Published on 29 June 2016
Author(s): Paul W Tebbey, PhD, Professor Paul J Declerck, PhD
adalimumab, biosimilar pharmaceuticals, consistency, glycosylation, immunogenicity, manufacturing
DOI: 10.5639/gabij.2016.0502.018
17.517 views
Published on 29 June 2016
Author(s): Niklas Ekman, PhD, Paul Cornes, MD, Professor Arnold G Vulto, PharmD, PhD, FCP
biological, biosimilar, cancer, European Union, healthcare costs, medicines, regulatory
DOI: 10.5639/gabij.2016.0502.020
9.110 views
Published on 29 June 2016
Author(s): Adrian Towse, MA, Jorge Mestre-Ferrandiz, PhD, Mikel Berdud, PhD
biosimilars, competition, incentives, real world data, savings, value for money
DOI: 10.5639/gabij.2016.0503.027
6.995 views
Published on 29 June 2016
Author(s): Professor Laszlo Endrenyi, PhD, DSc, Professor László Tóthfalusi, MSc, PhD
adjusted indirect comparisons, bioequivalence, generic drugs, generic medicines, interchangeability, switchability
DOI: 10.5639/gabij.2016.0502.014
7.646 views
Published on 27 June 2016
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2016.0502.024
7.219 views
Published on 27 June 2016
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2016.0502.023
13.325 views
Published on 08 June 2016
2.843 views